KER 216
Alternative Names: KER-216; m216; RKER-216Latest Information Update: 05 Mar 2024
At a glance
- Originator Keros Therapeutics
- Class Antianaemics; Antibodies
- Mechanism of Action ACVR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Iron deficiency anaemia